[1] Pusztaszeri MP, Bongiovanni M, Faquin WC.  Update on the cytologic and molecular features of medullary thyroid carcinoma[J]. Adv Anat Pathol, 2014, 21(1): 26-35.   doi: 10.1097/PAP.0000000000000004
[2] Mohammadi M, Hedayati M.  A brief review on the molecular basis of medullary thyroid carcinoma[J]. Cell J, 2017, 18(4): 485-492.   doi: 10.22074/cellj.2016.4715
[3] Lee CR, Lee S, Son H, et al.  Medullary thyroid carcinoma: a 30-year experience at one institution in Korea[J]. Ann Surg Treat Res, 2016, 91(6): 278-287.   doi: 10.4174/astr.2016.91.6.278
[4] Rajabi S, Hedayati M.  Medullary thyroid cancer: clinical characteristics and new insights into therapeutic strategies targeting tyrosine kinases[J]. Mol Diagn Ther, 2017, 21(6): 607-620.   doi: 10.1007/s40291-017-0289-5
[5] Asimakopoulos P, Nixon IJ, Shaha AR.  Differentiated and medullary thyroid cancer: surgical management of cervical lymph nodes[J]. Clin Oncol (R Coll Radiol), 2017, 29(5): 283-289.   doi: 10.1016/j.clon.2017.01.001
[6] Agrawal N, Jiao YC, Sausen M, et al.  Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS[J]. J Clin Endocrinol Metab, 2013, 98(2): E364-E369.   doi: 10.1210/jc.2012-2703
[7] Roy M, Chen H, Sippel RS.  Current understanding and management of medullary thyroid cancer[J]. Oncologist, 2013, 18(10): 1093-1100.   doi: 10.1634/theoncologist.2013-0053
[8] Cavedon E, Barollo S, Bertazza L, et al.  Prognostic impact of miR-224 and RAS mutations in medullary thyroid carcinoma[J]. Int J Endocrinol, 2017, 2017: 4915736-.   doi: 10.1155/2017/4915736
[9] Rodríguez-Antona C, Muñoz-Repeto I, Inglada-Pérez L, et al.  Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma[J]. Endocr Relat Cancer, 2013, 20(4): 611-619.   doi: 10.1530/ERC-12-0316
[10] Wells SA Jr, Asa SL, Dralle H, et al.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma[J]. Thyroid, 2015, 25(6): 567-610.   doi: 10.1089/thy.2014.0335
[11] Signorini PS, França MI, Camacho CP, et al.  A ten-year clinical update of a large RET p.Gly533Cys kindred with medullary thyroid carcinoma emphasizes the need for an individualized assessment of affected relatives[J]. Clin Endocrinol (Oxf), 2014, 80(2): 235-245.   doi: 10.1111/cen.12264
[12] Williams ED.  Histogenesis of medullary carcinoma of the thyroid[J]. J Clin Pathol, 1966, 19(2): 114-118.   doi: 10.1136/jcp.19.2.114
[13] Tashjian AH Jr, Melvin EW.  Medullary carcinoma of the thyroid gland. Studies of thyrocalcitonin in plasma and tumor extracts[J]. N Engl J Med, 1968, 279(6): 279-283.   doi: 10.1056/NEJM196808082790602
[14]

Cappagli V, Potes CS, Ferreira LB, et al. Calcitonin receptor expression in medullary thyroid carcinoma[J/OL]. PeerJ, 2017, 5: e3778[2019-04-02]. https://www.ncbi.nlm.nih.gov/pmc/journals/2057. DOI: 10.7717/peerj.3778.
[15] Trimboli P, Giovanella L.  Procalcitonin as marker of recurrent medullary thyroid carcinoma: a systematic review and meta-analysis[J]. Endocrinol Metab (Seoul), 2018, 33(2): 204-210.   doi: 10.3803/EnM.2018.33.2.204
[16] Trimboli P, Lauretta R, Barnabei A, et al.  Procalcitonin as a postoperative marker in the follow-up of patients affected by medullary thyroid carcinoma[J]. Int J Biol Markers, 2018, 33(2): 156-160.   doi: 10.1177/1724600817747518
[17] Hong MJ, Na DG, Baek JH, et al.  Impact of nodule size on malignancy risk differs according to the ultrasonography pattern of thyroid nodules[J]. Korean J Radiol, 2018, 19(3): 534-541.   doi: 10.3348/kjr.2018.19.3.534
[18] Valderrabano P, Klippenstein DL, Tourtelot JB, et al.  New American Thyroid Association sonographic patterns for thyroid nodules perform well in medullary thyroid carcinoma: institutional experience, systematic review, and meta-analysis[J]. Thyroid, 2016, 26(8): 1093-1100.   doi: 10.1089/thy.2016.0196
[19] Treglia G, Tamburello A, Giovanella L.  Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis[J]. Hormones (Athens), 2017, 16(4): 362-372.   doi: 10.14310/horm.2002.1756
[20] Souteiro P, Gouveia P, Ferreira G, et al.  68Ga-DOTANOC and 18F-FDG PET/CT in metastatic medullary thyroid carcinoma: novel correlations with tumoral biomarkers[J]. Endocrine, 2019, 64(2): 322-329.   doi: 10.1007/s12020-019-01846-8
[21] Zhang XW, Yan DG, Wang JY, et al.  Is new American Thyroid Association risk classification for hereditary medullary thyroid carcinoma applicable to Chinese patients? A single-center study[J]. Chin J Cancer Res, 2017, 29(3): 223-230.   doi: 10.21147/j.issn.1000-9604.2017.03.08
[22] Meijer JA, le Cessie S, van den Hout WB, et al.  Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis[J]. Clin Endocrinol (Oxf), 2010, 72(4): 534-542.   doi: 10.1111/j.1365-2265.2009.03666.x
[23]

Rusinek D, Chmielik E, Krajewska J, et al. Current advances in thyroid cancer management. are we ready for the epidemic rise of diagnoses?[J/OL]. Int J Mol Sci, 2017, 18(8): 1817[2019-04-02]. http://www.mdpi.com/journal/ijms. DOI: 10.3390/ijms18081817.
[24] Trimboli P, Treglia G, Guidobaldi L, et al.  Detection rate of FNA cytology in medullary thyroid carcinoma: a meta-analysis[J]. Clin Endocrinol (Oxf), 2015, 82(2): 280-285.   doi: 10.1111/cen.12563
[25] Frank-Raue K, Raue F.  Hereditary medullary thyroid cancer genotype-phenotype correlation[J]. Recent Results Cancer Res, 2015, 204: 139-156.   doi: 10.1007/978-3-319-22542-5_6
[26] Maia AL, Siqueira DR, Kulcsar MA, et al.  Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism[J]. Arq Bras Endocrinol Metabol, 2014, 58(7): 667-700.   doi: 10.1590/0004-2730000003427
[27] Kuo EJ, Sho S, Li N, et al.  Risk factors associated with reoperation and disease-specific mortality in patients with medullary thyroid carcinoma[J]. JAMA Surg, 2018, 153(1): 52-59.   doi: 10.1001/jamasurg.2017.3555
[28] Lacouture ME, Ciccolini K, Kloos RT, et al.  Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer[J]. Thyroid, 2014, 24(9): 1329-1340.   doi: 10.1089/thy.2013.0700
[29] 陈晓红.  甲状腺髓样癌的治疗策略[J]. 临床耳鼻咽喉头颈外科杂志, 2016, 30(21): 1667-1671.   doi: 10.13201/j.issn.1001-1781.2016.21.001
Chen XH.  Treatment strategy of medullary thyroid carcinoma[J]. J Clin Otorhinolaryngol Head Neck Surg, 2016, 30(21): 1667-1671.   doi: 10.13201/j.issn.1001-1781.2016.21.001
[30] Fialkowski E, DeBenedetti M, Moley J.  Long-term outcome of reoperations for medullary thyroid carcinoma[J]. World J Surg, 2008, 32(5): 754-765.   doi: 10.1007/s00268-007-9317-7
[31] Maxwell JE, Sherman SK, O'Dorisio TM, et al.  Medical management of metastatic medullary thyroid cancer[J]. Cancer, 2014, 120(21): 3287-3301.   doi: 10.1002/cncr.28858
[32] Steinfeld AD.  The role of radiation therapy in medullary carcinoma of the thyroid[J]. Radiology, 1977, 123(3): 745-746.   doi: 10.1148/123.3.745
[33] Samaan NA, Schultz PN, Hickey RC.  Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy[J]. J Clin Endocrinol Metab, 1988, 67(4): 801-805.   doi: 10.1210/jcem-67-4-801
[34] Jensen MH, Davis RK, Derrick L.  Thyroid cancer: a computer-assisted review of 5287 cases[J]. Otolaryngol Head Neck Surg, 1990, 102(1): 51-65.   doi: 10.1177/019459989010200109
[35] 何蕊, 朱高红.  甲状腺髓样癌靶向治疗的研究进展[J]. 国际放射医学核医学杂志, 2018, 42(2): 154-160.   doi: 10.3760/cma.j.issn.1673-4114.2018.02.010
He R, Zhu GH.  Research status of medullary thyroid carcinoma targeted therapy[J]. Int J Radiat Med Nucl Med, 2018, 42(2): 154-160.   doi: 10.3760/cma.j.issn.1673-4114.2018.02.010
[36]

Priya SR, Dravid CS, Digumarti R, et al. Targeted therapy for medullary thyroid cancer: a review[J/OL]. Front Oncol, 2017, 7: 238[2019-04-02]. https://www.frontiersin.org/articles/10.3389/fonc.2017.00238/full. DOI: 10.3389/fonc.2017.00238.
[37] Brose MS, Bible KC, Chow LQM, et al.  Management of treatment-related toxicities in advanced medullary thyroid cancer[J]. Cancer Treat Rev, 2018, 66: 64-73.   doi: 10.1016/j.ctrv.2018.04.007
[38] He R, Wang H, Su Y, et al.  Incorporating 131I into a PAMAM (G5.0) dendrimer-conjugate: design of a theranostic nanosensor for medullary thyroid carcinoma[J]. Rsc Advances, 2017, 7(26): 16181-16188.   doi: 10.1039/c7ra00604g
[39] 陈礼林, 谢丽君, 张海波, 等.  靶向肽结合131I-PAMAM(G5.0)抑制甲状腺髓样癌细胞增殖的研究[J]. 国际放射医学核医学杂志, 2017, 41(5): 307-313.   doi: 10.3760/cma.j.issn.1673-4114.2017.05.001
Chen LL, Xie LJ, Zhang HB, et al.  Effects of targeted peptide-conjugated 131I-PAMAM (G5.0) on the inhibition of medullary thyroid carcinoma cells proliferation[J]. Int J Radiat Med Nucl Med, 2017, 41(5): 307-313.   doi: 10.3760/cma.j.issn.1673-4114.2017.05.001
[40] 冯成涛, 张海波, 郑皓, 等.  131I-PAMAM(G5.0)介导靶向肽在甲状腺髓样癌模型中的实验研究[J]. 国际放射医学核医学杂志, 2019, 43(6): 528-537.   doi: 10.3760/cma.j.issn.1673-4114.2019.06.007
Feng CT, Zhang HB, Zheng H, et al.  Efficiacy of 131I-generation 5.0 polyamidamine-mediated targeting peptide in the mice with medullary thyroid carcinoma[J]. Int J Radiat Med Nucl Med, 2019, 43(6): 528-537.   doi: 10.3760/cma.j.issn.1673-4114.2019.06.007
[41] Moll UM, Marchenko N, Zhang XK.  p53 and Nur77/TR3—transcription factors that directly target mitochondria for cell death induction[J]. Oncogene, 2006, 25(34): 4725-4743.   doi: 10.1038/sj.onc.1209601
[42] Xu K, Liu PD, Wei WY.  mTOR signaling in tumorigenesis[J]. Biochim Biophys Acta, 2014, 1846(2): 638-654.   doi: 10.1016/j.bbcan.2014.10.007
[43] Zhang L, Liu W, Wang Q, et al.  New drug candidate targeting the 4A1 orphan nuclear receptor for medullary thyroid cancer therapy[J]. Molecules, 2018, 23(3): 565-.   doi: 10.3390/molecules23030565